Compare ARK Genomic Revolution ETF (ARKG) vs Anheuser-Busch Inbev SA (BUD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Anheuser-Busch Inbev SA — how do they compare? ARK Genomic Revolution ETF trades at $40.95, while Anheuser-Busch Inbev SA trades at $80.02 (market cap $153.32B). The key difference: Anheuser-Busch Inbev SA pays a 1.69% dividend while ARK Genomic Revolution ETF pays none. Which is the better fit depends on your goals.
| ARKG | BUD | |
|---|---|---|
Sector | Sector/Thematic | Consumer Staples |
52-Week High | $43.57 | $85.09 |
52-Week Low | $23.09 | $57.10 |
Market Cap | — | $153.32B |
Enterprise Value | — | $214.50B |
Dividend Yield | — | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
BUD trades at $79.61, up 0.34% on the day, with a bearish technical signal despite recent earnings beats. The company shows stable revenue near $59B and improving net margins, now at 11.9%. Analyst consensus is bullish with a $90.08 price target, supported by dividend payments and strategic investments in premiumization and digital expansion.
Outlook remains positive due to strong fundamentals and analyst support, but risks include industry volume declines and competitive pressures. The stock offers value through dividends and potential upside to target, though technical weakness suggests near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Anheuser-Busch Inbev SA
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Read more on BUD →
